Form 4: Recursion Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock at an average price of $12.0577 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock.
• The sale was executed under a 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $12.0577, with individual sales prices ranging from $11.64 to $12.45 per share.
• Following the transaction, Borgeson directly owns 7,272,809 shares of Recursion Pharmaceuticals' Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 plan are less likely to be interpreted as a negative signal, as these plans are pre-arranged and often used for diversification or liquidity purposes.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small volume of shares sold compared to the total outstanding shares.

Key Dates